Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Epistem Holdings signs landmark deal with medical fund

Agreement marks first investment by the fund, GHIF, which willl help Epistem launch its Gendrive platfrom in the world's poorest countries.

Epistem (LON:EHP) has agreed a landmark collaboration and funding deal with the Global Health Investment Fund to help launch its tuberculosis diagnostic platform in the world’s poorest countries.

Under the agreement, GHIF will lend Epistem US$8mln via a five-year convertible bond on favourable interest and conversion terms and support and facilitate the introduction, distribution and sale of the Genedrive platform around the world.

For its part, Epistem has agreed to make the platform affordable for patients in low- and middle-income countries.

Genedrive is a handheld tool that can diagnose TB within 30 minutes and that has been predicted to revolutionise the diagnosis of the disease in the third world.

Trials are currently ongoing in five countries, including India and Nigeria, after which regulatory submissions will be filed ahead of a global access and roll-out of the TB test.

GHIF, an investment fund set up to fund treatments for diseases associated with the poorest countries, such as tuberculosis, malaria, HIV/Aids and infant mortality, has agreed a conversion price of 489p on the bond, more than 50% higher than yesterday’s share price close, while the coupon is 5%.

According to GHIF, nearly 10mln cases of tuberculosis are reported annually resulting in approximately 1mln premature deaths each year.

Christopher Egerton-Warburton of GHIF said: “Epistem has sought to improve this situation with its Genedrive platform and as a result the GHIF is delighted to make this our first investment."

Matthew Walls, Epistem’s chief executive, added: "The support of the GHIF represents a very powerful endorsement of our strategy of developing Genedrive for infectious disease applications and our decision to target the tuberculosis market with our first assay.

“We are very excited about the potential of the GHIF's global network to financially support and commercially advance the roll-out of the Genedrive unit and our menu of new molecular diagnostic tests for 'Point of Care' application in low resource settings."

Separately, Epistem issued a trading update predicting underlying [EBITDA] losses of around £2.5mln this year reflecting the expenditure ahead of the launch of Genedrive. Net cash at 30 June was £4.2mln.

View full GDR profile View Profile

Genedrive PLC Timeline

Related Articles

bacteria
Thu
Following the disappointment of its DMD treatment over summer, Summit is leveraging its Discuva platform to develop new antibiotics, which doctors are in desperate need of
scientist in lab
07:52
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients
Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use